| Lisdexamfetamine Dimesylate | Shire | ||
| 20, 30, 40, 50, 60, 70 mg capsules |
More Than $1000 mn
|
||
|
Less Than 5
|
More Than 5
|
||
|
Less Than 5
|
Less Than 5
|
||
|
More Than 5
|
More Than 5
|
||
| Indicated for the treatment of: Attention Deficit Hyperactivity Disorder (ADHD) Moderate to Severe Binge Eating Disorder (BED) in adults | |||
|
Yes
| |||
| Vyvanse | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ******* | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** |
| ****** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** |
| ****** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** | **** ** ** |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ******* | *** \ ** | ** | **** ** ** | ******** ************ | *** ****** ******* |
| ****** | *** \ ** | *** *, **** | **** ** ** | ********* ******** | ****** **** ******** |
| ****** | *** \ ** | *** *, **** | **** ** ** | ******** | ******** ** ** *** **** |
| Lisdexamfetamine Dimesylate | Takeda | ||
| 10 mg; Capsule |
Less Than $1000 mn
|
||
|
Less Than 5
|
Less Than 5
|
||
|
Less Than 5
|
None | ||
|
More Than 5
|
More Than 5
|
||
| Vyvanse is indicated for the treatment of: Moderate to Severe Binge Eating Disorder (BED) in adults | |||
|
Yes
| |||
| Vyvanse | Patent 1 | Patent 2 | Patent 3 | Patent 4 | Patent 5 | Patent 6 | Patent 7 | Patent 8 | Patent 9 | Patent 10 | Patent 11 | Patent 12 | Patent 13 | Patent 14 | Patent 15 | Patent 16 | Patent 17 | Patent 18 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ******* (*******) | ********* | **** ** ** *** ** | **** ** ** *** ** | ********* | ********* | **** ** ** *** ** | ********* | **** ** ** *** ** | **** ** ** *** ** | ********* | **** ** ** *** ** | ********* | **** ** ** *** ** | ********* | **** ** ** *** ** | ********* | ********* | ********* |
| Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
|---|---|---|---|---|---|
| ******* (*******) | *** \ ** | *** **, **** | **** ** ** *** ** | ******** | ******** ** ** *** **** |
Download ParaIV Report